Proxy SNP Panels for HLA Risk Allele Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Routine HLA typing for pharmacogenomic risk prediction is not cost-effective due to the highly polymorphic nature of the HLA gene region, and existing proxy-SNPs have inadequate specificity and sensitivity across multi-ethnic populations, limiting their use in clinical practice for predicting drug-induced hypersensitivity reactions.
Innovation Solution
Identification of panels of proxy single nucleotide polymorphisms (SNPs) that are highly predictive of specific HLA risk alleles, such as HLA-B*57:01, HLA-B*15:02, HLA-A*31:01, and HLA-B*58:01, which can be used for cost-effective and rapid genotype-based screening across diverse populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If routine HLA typing is performed for pharmacogenomic risk prediction, then prediction accuracy is improved, but cost-effectiveness deteriorates due to the highly polymorphic nature of the HLA gene region
Solution Approach 1:
The patent uses proxy-SNPs (single nucleotide polymorphisms) that copy or represent the information contained in the highly polymorphic HLA gene region. Instead of directly typing the complex HLA genes, the invention identifies and tests specific SNP markers that are in linkage disequilibrium with HLA risk alleles, providing a simplified copy of the genetic information needed for prediction.
Solution Approach 2:
The patent extracts only the most relevant genetic markers (specific proxy-SNPs) from the entire HLA gene region. By identifying and isolating the key SNPs that are strongly associated with HLA risk alleles, the invention removes unnecessary complexity while retaining the essential predictive information.
2Ease of operation
If existing proxy-SNPs are used for HLA risk allele prediction, then screening simplicity is improved, but sensitivity and specificity deteriorate across multi-ethnic populations
Solution Approach 1:
The patent applies local quality by selecting different proxy-SNP panels tailored to specific ethnic populations. Recognizing that linkage disequilibrium patterns vary across populations, the invention identifies population-specific SNPs that maintain strong associations with HLA risk alleles in each ethnic group, thereby improving sensitivity and specificity for diverse populations while maintaining screening simplicity.
Data Source
AI summary
We have identified panels of proxy single nucleotide polymorphisms (SNPs) that are highly predictive of particular HLA risk alleles, and concordant across multi-ethnic populations. Accordingly, methods are provided involving clinical DNA testing for HLA panel markers to assess risk for life-threatening adverse drug reactions associated with the human leucocyte antigen (HLA) alleles HLA-B*57:01, HLA-B*15:02, HLA-A*31:01 and HLA-B*58:01. Methods of treating a subject with a drug associated with an adverse drug reaction (ADR) are provided. Based on the assessed risk to a subject for developing an adverse drug reaction in response to a drug, appropriate administrations of the drug can be made. In some embodiments of the method, the drug is administered when there is a low assessed risk of ADR in the subject. Alternatively, when there is a high assessed risk of ADR in the subject, a reduced dosage of the drug, or no drug, can be administered.